NETRIS Pharma will attend PEGS 2018 event in Boston, MA (April 30th-May 04th). Our CEO, Pr. Patrick Mehlen, will give a presentation on April 30th within the Oncology stream – Antibodies for Cancer Therapy. Pr. Mehlen will more particularly present our anti-Netrin-1 drug candidate NP137, which is currently in Phase I: http://www.pegsummit.com/Cancer-Antibodies/.
Our members attending the event will be pleased to meet you for discussing opportunities with potential partners and/or investors. Please do not hesitate to contact us.